Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
73.00    -0.50 (-0.68%)
Bid:
72.00
Ask:
74.00
Spread: 2.00 (2.778%)
Market Cap: £342.04m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Rule 8.1- (Curidium Medica Plc)

12 Feb 2009 13:23

RNS Number : 2369N
Avacta Group PLC
12 February 2009
Β 

ο»Ώ

Β  FORM 8.1

DEALINGS BY OFFERORS, OFFEREE COMPANIES OR THEIR ASSOCIATES

FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

(RulesΒ 8.1(a) and (b)(i)Β ofΒ theΒ TakeoverΒ Code)

1. KEY INFORMATION

Name of person dealingΒ (Note 1)

Avacta Group plc

Β 

Company dealt in

Curidium Medica plc

Β 

Class of relevant security to which the dealings being disclosed relateΒ (NoteΒ 2)

Ordinary Shares of 3p each

Date of dealing

12 February 2009

Β 

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

(a) InterestsΒ and short positionsΒ (following dealing) in the class of relevant security dealt inΒ (Note 3)

Long

Short

Number (%)

Number (%)

(1) Relevant securitiesΒ 

1 (

(2) DerivativesΒ (other than options)

(3)Β OptionsΒ and agreements to purchase/sell

Total

(b) InterestsΒ and short positionsΒ in relevant securities of the company, other than theΒ classΒ dealt inΒ (Note 3)

Class of relevant security:

Long

Short

Number (%)

Number (%)

(1) Relevant securitiesΒ 

(2) DerivativesΒ (other than options)

(3)Β OptionsΒ and agreements to purchase/sell

Total

(c) Rights to subscribeΒ (Note 3)

Class of relevant security:

Details

3. DEALINGSΒ (Note 4)

(a) Purchases and sales

Purchase/sale

Number of securities

Price per unitΒ (Note 5)

Purchase

1

30.8p

(b) Derivatives transactions (other than options)

Product name,Β 

e.g. CFD

Long/shortΒ (Note 6)

Number of securitiesΒ (Note 7)

Price per unitΒ (Note 5)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,

e.g.Β callΒ option

Writing, selling, purchasing, varying etc.

Number of securitiesΒ to which the option relatesΒ (Note 7)

Exercise

priceΒ 

Type,Β e.g. American, European etc.

ExpiryΒ 

date

Option money

paid/receivedΒ per unitΒ (Note 5)

(ii) Exercising

Product name,Β e.g.Β call option

Number of securitiesΒ 

Exercise priceΒ per unitΒ (Note 5)

(d) Other dealings (including new securities)Β (Note 4)

Nature of transactionΒ (Note 8)

Details

PriceΒ per unitΒ (if applicable)Β (Note 5)Β 

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relatingΒ toΒ the voting rights of any relevant securities under any option referred to on this form orΒ relating to the voting rights orΒ future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached?Β (Note 9) NO

Date of disclosure

12 February 2009

Β 

Contact name

Henry Turcan

Β 

Telephone number

020 7562 4700

Β 

Name of offeree/offerorΒ with whichΒ associated

Avacta Group plc

Β 

Specify category and nature of associate statusΒ (Note 10)

Offeror

Β 

Notes

TheΒ NotesΒ onΒ Form 8.1 can be viewed on the Takeover Panel's website atΒ www.thetakeoverpanel.org.uk

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DCCZGGMZFZMGLZM
Date   Source Headline
5th Jun 20267:00 amRNSOversubscribed Strategic Equity Fundraise of £9m
1st Jun 20263:00 pmRNSBlock Listing - Application to AIM
1st Jun 20267:00 amRNSClinical data on AVA6000 in salivary gland cancers
29th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
29th May 20267:00 amRNSBoard Director Changes
19th May 20267:00 amRNSUnaudited Preliminary Full Year 2025 Results
13th May 20267:00 amRNSNotice of Preliminary Results and Presentation
13th May 20267:00 amRNSIssue of Equity and Total Voting Rights
6th May 20267:00 amRNSPre|CISION® payload release vs approved ADCs
28th Apr 20267:00 amRNSBlock Listing Six Monthly Return
21st Apr 20267:00 amRNSAvacta data AACR underline AVA6103 profile
14th Apr 202611:37 amRNS-RChristina Coughlin - In Vivo 2026 Rising Leader
9th Apr 20267:00 amRNSQ1 2026 Business Update
8th Apr 20267:00 amRNS-RAvacta Announces Science Day 2026
31st Mar 20267:00 amRNSFirst patient treated in Phase 1 trial of AVA6103
27th Mar 20267:00 amRNSResult of Oversubscribed Fundraise
26th Mar 20265:16 pmRNSProposed Fundraise to raise approximately £10m
26th Mar 20264:44 pmRNSIssue of Equity
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
24th Feb 20267:00 amRNSPreCISION payload delivery advantage over ADC
18th Feb 20267:00 amRNS-RAvacta to Participate in Conference March 2026
9th Feb 20267:00 amRNSAppointment of CSO
3rd Feb 20267:00 amRNSFaridoxorubicin Program Clinical Updates
21st Jan 20267:00 amRNSFDA Clearance of IND Application for AVA6103
20th Jan 20267:01 amRNSYear-end trading update
20th Jan 20267:00 amRNSAppointment of Nominated Adviser & TVR
18th Dec 20257:00 amRNS-RAvacta reports new AVA6103 pharmacology data
17th Dec 20257:00 amRNSFaridoxorubicin Phase 1b SGC data
8th Dec 20257:00 amRNSPreliminary Data in Faridoxorubicin Phase 1b Trial
3rd Nov 20258:24 amRNSCompletion of Placing and TVR
27th Oct 20255:39 pmRNSBlock Listing Six Monthly Return
27th Oct 20257:00 amRNSAvacta presents preclinical data at AACR-NCI-EORTC
23rd Oct 20255:00 pmRNS-RNotice of Investor Presentation
20th Oct 20257:01 amRNSEquity fundraise of £16 million
20th Oct 20257:00 amRNSAvacta Presents Phase 1a Data for Faridoxorubicin
13th Oct 20257:00 amRNSAvacta to present data at EORTC-NCI-AACR
30th Sep 20257:00 amRNSInterim Half Year Results 2025
15th Sep 20257:00 amRNSNotice of Interim Results
9th Sep 20257:00 amRNS-RShortlisted for AIM Awards Technology of the Year
1st Sep 20257:00 amRNSAvacta completes sale of Coris Bioconcept
29th Aug 20257:00 amRNSAmendments to Convertible Bond + equity fundraise
30th Jul 20257:00 amRNSAvacta to Present at ESMO Congress
28th Jul 20257:48 amRNSAgreement to Sell Coris Bioconcept SRL
21st Jul 20257:00 amRNSPayment of Convertible Bond Installment
17th Jul 20257:00 amRNSEquity fundraise of £3.25 million
2nd Jul 20255:00 pmRNSResult of AGM
2nd Jul 20257:00 amRNSQ2 2025 Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.